Spirovac L5

Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin

For use in cattle only

Before use, read the full directions and precautions.

This product has been shown to be effective for the vaccination of healthy cattle, including pregnant cows and heifers, 4 weeks of age and older against disease caused by Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. A duration of immunity of at least 12 months has been demonstrated against renal infection due to L. hardjo. Duration of immunity against the remaining fractions has not been established. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

This product has been shown to be effective against fetal, genital, and renal infections, and leptospiruria caused by L. hardjo bovis.

PRODUCT DESCRIPTION:

Spirovac L5 contains a specially prepared, inactivated and adjuvanted unique strain of Leptospira borgpetersenii serovar hardjo-bovis together with inactivated and adjuvanted cultures of L. pomona, L. grippotyphosa, L. canicola and L. icterohaemorrhagiae.

Directions For Use

General Directions: Vaccination of healthy cattle, including pregnant cows and heifers, is recommended. Shake well. Aseptically administer 2 mL subcutaneously or intramuscularly high on the side of the neck.

Primary Vaccination: Healthy cattle should receive 2 doses administered 4-6 weeks apart. When used to prevent genital or fetal infection, the second dose should be administered at least 2 weeks prior to breeding.

Revaccination: Historically, annual revaccination with this product has been recommended. The need for annual booster vaccinations has not been established for this product; consultation with a veterinarian or the manufacturer is recommended.

Good animal husbandry and herd health management practices should be employed.

Precautions

Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine.

Do not vaccinate within 21 days before slaughter.

Contains thimerosal as a preservative.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

Do not mix with other products.

In case of human exposure, contact a physician.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

For veterinary use only

VLN 190/PCN 2665.06

Zoetis Inc., Kalamazoo, MI 49007, USA

CPN: 3690215.4